Humana and Amgen are collaborating on an effort to use data and real-world evidence to find ways to improve health outcomes and improve provider efficiency.

The agreement between Humana, a health plan administrator, and Amgen, a biotechnology company, will initially focus on six medical conditions that are widespread and expensive to treat. First to be studied by the initiative are cardiovascular disease, osteoporosis, neurologic disorders, inflammatory diseases and cancer.

Register or login for access to this item and much more

All Digital Insurance content is archived after seven days.

Community members receive:
  • All recent and archived articles
  • Conference offers and updates
  • A full menu of enewsletter options
  • Web seminars, white papers, ebooks

Don't have an account? Register for Free Unlimited Access